NovaBay Pharma (NBY) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $1.95 --0%
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
NovaBay Pharma (NYSE: NBY) reported Q4 EPS of ($1.37), $0.15 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $3.15 million.
For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- First Solar (FSLR) call put ratio 6.3 calls to 1 put with a focus on January calls as share price up 9.4%
- Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
